Breast cancer remains a significant health challenge, but advancements in targeted therapies have dramatically improved treatment options and patient prognoses. Olaparib, a PARP inhibitor, has emerged as a crucial therapeutic agent, particularly for patients diagnosed with HER2-negative breast cancer who carry BRCA1 or BRCA2 gene mutations. BRCA mutations are inherited genetic alterations that significantly increase a woman's risk of developing breast, ovarian, and other cancers. These mutations compromise the cell's ability to repair DNA damage, making cancer cells particularly susceptible to treatments that further disrupt DNA integrity. Olaparib capitalizes on this vulnerability. By inhibiting PARP, an enzyme involved in DNA repair, Olaparib prevents cancer cells with BRCA mutations from repairing damage, leading to their death through a process called synthetic lethality. Clinical studies, such as the OlympiAD trial, have demonstrated the significant benefits of Olaparib in this patient population. For early-stage breast cancer patients with a high risk of recurrence, Olaparib, when used as adjuvant therapy after chemotherapy, has shown improvements in invasive disease-free survival and overall survival. In the context of metastatic HER2-negative breast cancer with BRCA mutations, Olaparib offers a targeted treatment option that can help manage disease progression and improve quality of life. The availability of Olaparib through reliable manufacturers and suppliers in China ensures that this vital treatment can reach patients who need it most. As research continues to expand the understanding of PARP inhibitors and their applications, Olaparib stands as a testament to the power of precision medicine in transforming cancer care. Patients and healthcare providers alike rely on the consistent quality and availability of Olaparib to achieve optimal therapeutic results.